BlueBird Bio Wounded After Roth Downgrade

bluebird bio Inc BLUE shares are trading lower by $2.00 at $76.65 in Monday's session.

Its four-day rally from its January 31 low ($67.10) to as high as $78.80 in Friday's session before closing at $78.65 has been interrupted by a Roth Capital downgrade. Before the open, the firm downgraded the issue from Buy to Neutral.

In a see-saw session, the issue has found support just ahead of Friday's low ($75.15), only reaching $75.40. On the upside, the issue hasn't been able reach its closing price from Friday ($78.65) as $77.75 stands a the current high for the session. That was the highest close for the issue since December 6, when it ended that session at $78.95.

The company won't Q4 earnings until February 22. Street estimates for EPS are $(1.86) on revenues of a paltry $1.76 million.